tiprankstipranks
Advertisement
Advertisement

KAPA Stock Latest News

Kairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence
Company AnnouncementsKairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence
7d ago
KAPA
Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
PremiumRatings
Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
25d ago
KAPA
Kairos Pharma, Bayer partner on prostate cancer therapy
PremiumCompany Announcements
Kairos Pharma, Bayer partner on prostate cancer therapy
1M ago
8K
KAPA
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
PremiumThe Fly
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
1M ago
KAPA
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
PremiumThe Fly
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
1M ago
KAPA
Kairos Pharma Shareholders Approve Reverse Split, Governance Measures
PremiumCompany AnnouncementsKairos Pharma Shareholders Approve Reverse Split, Governance Measures
2M ago
8K
KAPA
Kairos Pharma outlines mid-year oncology pipeline and funding plans
Premium
Company Announcements
Kairos Pharma outlines mid-year oncology pipeline and funding plans
3M ago
8K
KAPA
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
Premium
The Fly
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
3M ago
KAPA
Kairos Pharma Highlights Clinical Programs at LD Micro
PremiumCompany Announcements
Kairos Pharma Highlights Clinical Programs at LD Micro
3M ago
8K
KAPA
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
PremiumRatings
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
5M ago
KAPA
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
PremiumCompany Announcements
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
6M ago
8K
KAPA
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
PremiumThe Fly
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
6M ago
KAPA
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
PremiumThe FlyKairos Pharma to acquire to two clinical-stage oncology assets from Celyn
6M ago
KAPA
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
Premium
Company Announcements
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
6M ago
8K
KAPA
Kairos Pharma files $75M mixed securities shelf
Premium
The Fly
Kairos Pharma files $75M mixed securities shelf
7M ago
KAPA
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
PremiumRatings
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
9M ago
KAPA
Kairos Pharma Approves RSUs and Cash Bonuses
PremiumCompany Announcements
Kairos Pharma Approves RSUs and Cash Bonuses
10M ago
8K
KAPA
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
PremiumRatings
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
11M ago
KAPA
Kairos Pharma to Present at ESMO Congress 2025
PremiumCompany Announcements
Kairos Pharma to Present at ESMO Congress 2025
11M ago
8K
KAPA
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
PremiumRatingsPromising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
11M ago
KAPA
Kairos Pharma Reports Positive Phase 2 Trial Results
Premium
Company Announcements
Kairos Pharma Reports Positive Phase 2 Trial Results
11M ago
8K
KAPA
Kairos Pharma announces interim efficacy analysis of ENV105
Premium
The Fly
Kairos Pharma announces interim efficacy analysis of ENV105
11M ago
KAPA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >